Table 1.

Predictors of Recurrence Free Survival

		Recurrence Free Survival
Variable	No. of Patients	Univariate Analysis			Multivariate Analysis
Variable	No. of Patients	P	HR	95% CI	P	HR	95% CI
Age
<50 years	36
≥50 years	12	0.188	1.75	0.76-4.00	NS
Pathologic Response
Major	19	0.01	0.32	0.133-0.758	NS
Minor	29
Tumor Thickness at TNI
≤3 mm	23
>3 mm	25	0.004	3.02	1.37-6.65	0.001	4.11	1.76-9.61
# Tumor Nodules
<2	28	0.467	1.32	0.62-2.79
≥2	20
Tumor Size
≤5 cm	43
>5 cm	5	0.006	4.24	1.51-11.94	NS
Liver Resection
major	30	0.851	1.07	0.51-2.26
minor	18
Surgical Margin
positive	4	0.009	5.20	1.50-17.97	0.002	8.3	2.20-31.28
negative	44
Tumor Type
ductal type	44	0.920	1.06	0.32-3.57
lobular type	3
mixed type	1
Estrogen Receptor Status
positive	31	0.340	0.66	0.28-1.54
negative	14
no data	10
Progesterone Receptor Status
positive	23	0.882	0.94	0.43-2.06
negative	21
no data	4
ER and PR Status
positive	14	0.340	1.51	0.647-3.53
negative	31
no data	3
Her2/neu Status
positive	20	0.583	0.795	0.35-1.81
negative	21
no data	7
Synchronous liver Disease
yes	16	0.443	0.71	0.30-1.67
no	32
Primary Neoadjuvant Chemo
yes	17	0.244	1.63	0.74-3.56
no	31
Neoadjuvant Chemotherapy for Liver Metastasis>6 cycle
yes	32	0.349	0.67	0.29-1.55
no	16

P, p value; HR, Hazard Ratio; NS, not significant; ER, estrogen receptor; PR, progesterone receptor; Chemo, chemotherapy.